Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief

This article was originally published in The Tan Sheet

Executive Summary

Asthma inhaler bill vote delayed; fatal plant explosion rocks krill oil producer Neptune; ProPhase grows despite weak cold/flu trend; FTC general counsel leaves; Nu Skin acquires NOX Technologies; more news in brief.

You may also be interested in...



Sales & Earnings In Brief: Prestige Brands, Merck, Herbalife, Reckitt

Prestige feels effects of J&J relaunches; Merck CEO urges long view on Consumer Care; Herbalife still growing in North America; Reckitt boosts brand equity investments; sales of Bayer’s OTCs “gratifying;” Church & Dwight gummies best expectations; more Sales & Earnings In Brief.

Sales & Earnings In Brief: Prestige Brands, Merck, Herbalife, Reckitt

Prestige feels effects of J&J relaunches; Merck CEO urges long view on Consumer Care; Herbalife still growing in North America; Reckitt boosts brand equity investments; sales of Bayer’s OTCs “gratifying;” Church & Dwight gummies best expectations; more Sales & Earnings In Brief.

In Brief

Bayer buys herbal firm; NBTY notes bright spots, hires international leader; Neptune prepares to rebuild; P&G suit targets CAO’s tooth whiteners; CSPI supports restricting St. John’s wort; Coppertone schools parents; Hillary Clinton will speak at NACDS Total Store Expo.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS106093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel